在分析师前景复杂和临床开发持续的情况下，Belite Bio的空头持仓在12月暴跌45%。 Belite Bio's short interest plummeted 45% in December amid mixed analyst outlooks and ongoing clinical development.

12月,Belite Bio(BLTE)的短期利息下降45.2%,降至294 199股,日复一日的覆盖比率为0.8。 Belite Bio (BLTE) saw short interest drop 45.2% in December, falling to 294,199 shares, with a days-to-cover ratio of 0.8. 股票的营业额为154.93美元,市场上限为58.1亿美元,负P/E为80.69美元。 The stock opened at $154.93, with a market cap of $5.81 billion and a negative P/E of -80.69. 该公司报告该季度的EPS为0.95美元,但分析家预测全年损失为1.17美元。 The company reported $0.95 EPS for the quarter, but analysts project a $1.17 loss for the full year. 综合评价为"适度买入"和175.33美元的平均价格目标反映了分析师的不同看法,包括Cantor Fitzgerald的"超重"和BTIG的"卖出". A consensus "Moderate Buy" rating and $175.33 average price target reflect mixed analyst views, including "Overweight" from Cantor Fitzgerald and "Sell" from BTIG. 临床阶段生物技术侧重于新陈代谢和煽动性疾病,有多种候选疾病在早期发展。 The clinical-stage biotech focuses on metabolic and inflammatory diseases with multiple candidates in early development.